Related Experiment Videos
Novel approaches in development for the treatment of pancreatic cancer
J Butera1, M Malachovsky, R Rathore
1Department of Medicine, Brown University, Providence Rhode Island, USA.
Abstract:
Pancreatic adenocarcinomas are among the most resistant neoplasms to conventional chemotherapeutics. This has prompted intense investigations of novel non-cytotoxic agents based on new understandings of the molecular pathobiology of human malignancies. This review will focus on the potential uses of three new classes of agents: farnesyl transferase (FTPase) inhibitors, matrix metalloproteinase inhibitors (MMPI's) and antibodies to the HER-2/neu oncogene. When used as single agents, FTPase inhibitors and MMPI's may be cytostatic, helping to delay the growth of these cancers. All three classes of agents may have the greatest benefit when used in conjunction with traditional anticancer modalities. The biology of these agents will reviewed.
Insights
Novel non-cytotoxic agents, including farnesyl transferase inhibitors and matrix metalloproteinase inhibitors, show potential for treating pancreatic cancer. These agents may offer the greatest benefit when combined with traditional chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Pancreatic adenocarcinomas exhibit high resistance to conventional chemotherapeutics.
- New therapeutic strategies are needed, driven by advancements in understanding cancer molecular pathobiology.
Purpose of the Study:
- To review the potential applications of three novel non-cytotoxic agent classes in treating pancreatic cancer.
- To explore the role of farnesyl transferase (FTPase) inhibitors, matrix metalloproteinase inhibitors (MMPIs), and HER-2/neu antibodies.
Main Methods:
- Review of existing literature on FTPase inhibitors, MMPIs, and HER-2/neu antibodies.
- Analysis of the biological mechanisms and potential therapeutic benefits of these agents.
Main Results:
- FTPase inhibitors and MMPIs may exhibit cytostatic effects as single agents, potentially delaying tumor growth.
- All three classes of agents show promise for enhanced efficacy when used in combination with traditional anticancer treatments.
Conclusions:
- Novel agents like FTPase inhibitors, MMPIs, and HER-2/neu antibodies represent promising avenues for pancreatic cancer therapy.
- Combination therapy involving these novel agents and conventional modalities may offer the most significant clinical benefit.